scispace - formally typeset
R

Ryan T. Phan

Researcher at Columbia University

Publications -  6
Citations -  1140

Ryan T. Phan is an academic researcher from Columbia University. The author has contributed to research in topics: Germinal center & Somatic hypermutation. The author has an hindex of 4, co-authored 4 publications receiving 1000 citations. Previous affiliations of Ryan T. Phan include Massachusetts Institute of Technology.

Papers
More filters
Journal ArticleDOI

The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

TL;DR: It is reported that BCL6 suppresses the expression of the p53 (also known as tp53) tumour suppressor gene and modulates DNA damage-induced apoptotic responses in germinal-centre B cells and implies that deregulated BCL 6 expression contributes to lymphomagenesis in part by functional inactivation of p53.
Journal ArticleDOI

The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry

TL;DR: It is shown that the GC reaction required biphasic regulation of expression of the cell-cycle regulator c-Myc that involved its transient induction during early GC commitment, its repression by Bcl-6 in DZ B cells and its reinduction in B cells selected for reentry into the DZ.
Journal ArticleDOI

Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells.

TL;DR: These findings suggest that the extent of genotoxic stress controls the fate of germinal center B cells by means of Bcl-6, a transcription factor required for the formation of Germinal centers.
Journal ArticleDOI

The BCL6 Proto-Oncogene Suppresses p53 Expression in Germinal-Center B Cells.

TL;DR: Results indicate that one function of BCL6 is to allow GC B cells (centroblasts) to constitutively proliferate and to sustain the physiologic DNA breaks required for immunoglobulin switch recombination and somatic hypermutation without inducing p53-related responses.
Journal ArticleDOI

Validation of a gene expression signature to measure immune quiescence in kidney transplant recipients in the CLIA setting.

TL;DR: The validation of a non-invasive molecular diagnostic assay, AlloMap Kidney, using peripheral blood, demonstrating the sensitivity and specificity for allograft rejection and immune quiescence in kidney transplant patients is reported.